Topical anesthesia

Mritunjay Kumar, Rajiv Chawla, Manish Goyal
Department of Anesthesiology and Intensive Care, Govind Ballabh Pant Hospital, New Delhi, India

Abstract

Topical anesthetics are being widely used in numerous medical and surgical sub-specialities such as anesthesia, ophthalmology, otorhinolaryngology, dentistry, urology, and aesthetic surgery. They cause superficial loss of pain sensation after direct application. Their delivery and effectiveness can be enhanced by using free bases; by increasing the drug concentration, lowering the melting point; by using physical and chemical permeation enhancers and lipid delivery vesicles. Various topical anesthetic agents available for use are eutectic mixture of local anesthetics, ELA-max, lidocaine, epinephrine, tetracaine, bupivacaine, 4% tetracaine, benzocaine, proparacaine, Betacaine-LA, topicaine, lidoderm, S-caine patch™ and local anesthetic peel. While using them, careful attention must be paid to their pharmacology, area and duration of application, age and weight of the patients and possible side-effects.

Key words: Topical anesthesia, Eutectic mixture of local anesthetics, iontophoresis, local anesthetic, skin permeation enhancer, sonophoresis, uses and side-effects of topical anesthetics

Introduction

Injections of local anesthetics are painful. It can worsen needle anxiety, and can cause tissue edema, which distorts the surgical site. Use of topical anesthesia can avoid all these problems and is becoming a routine in clinical practice.

Topical anesthesia is defined as superficial loss of sensation in conjunctiva, mucous membranes, or skin, produced by direct application of local anesthetic solutions, ointments, gels or sprays.

The first local anesthetic (cocaine) was a topical anesthetic and was serendipitously discovered to have anesthetic properties, when Albert Niemann in 1860, like many chemists of that era tested his newly isolated compound and noted that it caused numbing of the tongue.[1] In 1884, Karl Koller, an ophthalmic surgeon, demonstrated that general anesthesia could be avoided for ophthalmic procedures by using cocaine application to the conjunctiva.[2] The discovery of various amide and ester local anesthetics, their topical preparations and delivery systems in due course of time opened the gate of immense possible uses of topical anesthetics.

Mechanism of Action

Topical anesthetics reversibly block nerve conduction near their site of administration by targeting free nerve endings in the dermis or mucosa, thereby producing temporary loss of sensation in a limited area. Nerve impulse conduction is blocked by decreasing nerve cell membrane permeability to sodium ions, possibly by competing with calcium-binding sites that control sodium permeability. This change in permeability decreases depolarization and increases excitability threshold until the ability to generate an action potential is lost.

Pharmacology

Topical anesthetics are weak bases. They are made up of three important components: An aromatic ring, an intermediate length ester or amide linkage and a tertiary amine. The aromatic ring is primarily responsible for the lipid solubility that allows diffusion across the nerve cell membrane, determining the intrinsic property of these agents.[3-5] Protein binding of these agents depend on both the aromatic and amine portion.[6]
Onset of action, anesthesia depth, and duration of action are determined by the pKa level, pH level, lipid solubility, protein binding, and vasodilatory effects of the specific local anesthetic. Other factors, which play important roles, are the site of application (faster onset at mucosa and sites with thin stratum corneum), vascularity of tissues in the area applied, the surface area, and duration of application.

Ester-type topical anesthetics are metabolized by plasma cholinesterase and other nonspecific esterases, while amide anesthetics are primarily metabolized in the liver via microsomal enzymes. Ester anesthetics are known to cause allergic manifestations on contact, while it is said to be a rare occurrence with amide anesthetics.[7-9] Para-amino benzoic acid (PABA), an ester hydrolysis metabolite is also known to be associated with allergic manifestations.[10]

**Skin Penetration Routes**

There are three pathways to cross the stratum corneum, which is the main barrier for topical anesthetic agent delivery:[11]

1. Intercellular route (through the intercellular spaces of the cornified keratinocytes)
2. Para or transcellular route (through the cornified cells)
3. Transappendageal route or shunt pathway (through the openings of the hair follicles and sweat glands) [Figure 1].

Topical anesthetics are also able to penetrate mucosal surfaces, such as the mouth, genitals, and conjunctiva more easily than through a keratinized surface because of the absence of a stratum corneum.

**Factors Determining the Dermal Drug Delivery**

**Drug form**

Free bases are lipophilic and can penetrate the stratum corneum on its own whereas the salt forms require special delivery systems to do so.

**Melting point and eutectic mixtures**

The lower the melting point, the better the penetration is. Eutectic mixtures have a lower melting point, thus better penetration than either component by itself.

**Concentration of drug in vehicle**

Higher the concentration of drug in the vehicle, higher the rate of penetration.

**Skin permeation enhancers**

These compounds, promote skin permeability by increasing the permeability of the stratum corneum temporarily and reversibly. They can be:

- a. Solvents, e.g., water, alcohols, glycerol, low molecular weight ethers, sucrose esters,[12] silicone fluids etc.,
- b. Surfactants[13] e.g., ionic, nonionic, bile salts or
- c. Miscellaneous chemicals, e.g., urea, anticholinergic drugs.

Permeation enhancers under trial are eucalyptol, soya bean casein.[14]

**Physical means of enhancing permeation**

Skin penetration of topically applied anesthetics can be enhanced by following physical measures:

- a. Exfoliation of the skin.
- b. Degreasing by alcohol.
- c. By covering the application area with a dressing or patch of nonporous material such as micropore and tegaderm.

Following energy-dependent active measures are being used/tried to enhance drug delivery across the skin.[15]

- d. Iontophoresis [Figure 2] (low voltage current to drive charged drugs through skin).[16]

  The amount of drug delivered via iontophoresis is dependent on the current and the duration of delivery. Lignocaine HCl 10%/adrenaline 0.1% topical iontophoretic patch (LidoSite) is the first Food and Drug Administration (FDA) approved prefilled active anesthetic patch. Disadvantages of iontophoretis technique are:
i. Can cause skin irritation at higher current densities or upon longer application.\(^{[17]}\)  
ii. Prolonged application can also cause electrochemical polarization in the skin, which decreases the magnitude of current flow through the skin,  
iii. The mild electrical sensation can be uncomfortable for some patients.  
iv. The apparatus is expensive and bulky, and  
v. It cannot be used over large surface areas of the body.  

e. Electroporation (uses short electrical impulses of high voltage to create transient pores in the skin).\(^{[18]}\) The electrical pulses are applied only for fraction of a second; the interval between subsequent pulses allows the skin to depolarize.\(^{[19]}\) Therefore, polarization of skin does not interfere with the current flow or drug diffusion.  
f. Sonophoresis or phonophoresis [Figure 3] (low frequency, ultrasonic energy to disrupt stratum corneum)\(^{[20]}\) — The ultrasound enhances drug delivery by cavitation, micro steaming and heating. The frequencies used can be high in the range of 0.7-16 MHz or low frequency in the range of 20-100 kHz. Low frequency sonophoresis can allow transdermal delivery of both hydrophilic and high molecular mass permeants at therapeutic levels.  
g. Magnetophoresis/magnetokinesis (application of magnetic field to enhance permeation).\(^{[21]}\)  
h. Thermal energy (heat à increases skin permeability).  
i. Erbium:YAG laser pretreatment.\(^{[22]}\)  
j. Skin pretreatment with a hand-applied, plastic microneedle array.\(^{[23]}\)  

**Delivery from Lipid Vesicles**

Liposomes, niosomes, and transfersomes are examples of lipid vesicles.  

Liposomes are microscopic vesicles, which are composed of one or more lipid bilayers arranged in concentric fashion enclosing an equal number of aqueous compartments capable of entrapping lipid soluble or water-soluble drugs. The lipids used are typically phospholipids such as lecithin. Drug molecules can either be encapsulated in the aqueous space or intercalated into the lipid bilayer depending upon its physicochemical characteristics.\(^{[24,25]}\) Studies with radioactive or fluorescence-labeled phospholipids have shown that the liposomes disperse in the upper layers of the stratum corneum, without further penetration into the epidermis, dermis or deeper.\(^{[26]}\) Fisher et al. in their study found that 5% liposome-encapsulated tetracaine produced better superficial local anesthesia than 5% eutectic mixture of local anesthetics (EMLA).\(^{[27]}\) Disadvantages of liposomes are their instability, and the predisposition of phospholipids to oxidative degradation.

Niosomes (microvesicles) are similar to liposomes, but are prepared from nonionic surfactants. They tend to be smaller in diameter than liposomes, and may have unilamellar (one layer), or multilamellar structures. They are more stable and may provide faster penetration to the stratum corneum than liposomes. They do not go deeper either.

Transfersomes are prepared using bile salt (sodium cholate) molecules. Unlike liposomes, transfersomes appear to be highly deformable and researchers claim that they can transport through pores, which are 5 times smaller than their size.

**Various Topical Preparations**

**Eutectic mixture of local anesthetics**

Eutectic mixtures are compounds, which melt at lower temperatures than any of their components, permitting higher concentrations of anesthetics for use. It is 5% oil in water emulsion cream with a melting point of 18°C and consists of 25 mg/mL of lignocaine, 25 mg/mL of prilocaine, a thickener, an emulsifier, and distilled water adjusted to a pH level of 9.4. EMLA is applied in a thick layer (1-2 g/10 cm², up to a maximal dose of 20 g/200 cm²) to intact skin. Pediatric dosing is shown in Table 1. After application, the area is covered with a patch of tegaderm or clear plastic wrap to facilitate penetration through the stratum corneum. Depth of anesthesia depends on the contact time with EMLA. Anesthetic effect has been shown to reach a maximal depth of 3 mm after a 60-min application, and 5 mm after a 120-min application. Dermal analgesia can be expected to increase for up to 3 h

| Age and body weight requirements (kg) | Maximum total dose of EMLA cream (g) | Maximum application area (cm²) | Maximum application time (h) |
|-------------------------------------|-------------------------------------|-------------------------------|------------------------------|
| 0 up to 3 months or <5              | 1                                   | 10                            | 1                            |
| 3 up to 12 months and >5            | 2                                   | 20                            | 4                            |
| 1-6 years and >10                   | 10                                  | 100                           | 4                            |
| 7-12 years and >20                  | 20                                  | 200                           | 4                            |

EMLA = Eutectic mixture of local anaesthetics

---

Figure 3: Sonophoresis
under occlusive dressing and persist for 1-2 h after removal of the cream. EMLA should not be applied to the palms and soles because of variable penetration. EMLA is a pregnancy category B agent, but caution should be exercised when being administered to a nursing mother, because lignocaine is excreted through breast milk (AstraZeneca insert).

**Tetracaine, adrenaline (epinephrine), and cocaine (TAC)**
Consists of 0.5% tetracaine, 0.05% adrenaline, and 11.8% cocaine. It was the first topical anesthetic mixture found to be effective for nonmucosal skin lacerations to the face and scalp. A dose of 1 ml/cm of laceration can be applied using a cotton-tipped applicator with firm pressure that is maintained for 20-40 min. However, it is no longer being used because of general concern about toxicity and expense, and federal regulatory issues involving medications containing cocaine.[28]

**Lidocaine, epinephrine, and tetracaine (LET)**
Safer and more cost-effective alternative to TAC, contains 4% lignocaine with 0.1% epinephrine and 0.5% tetracaine. LET is used on nonmucosal skin lacerations by placing a few drops directly into the wound. A cotton-tipped applicator with 1-3 mL of the gel or solution is then applied directly to the wound with firm pressure for 15-30 min. It can be safely used in children older than 2 years of age. LET is slightly less effective on extremity lacerations. Because LET contains epinephrine, application to end-arteriolar parts of the body, such as the digits, should be avoided. Caution must also be exercised when contemplating the use of LET in contaminated wounds, complex wounds, or wounds larger than 6 cm. LET and TAC do not work on intact skin.[28]

**Bupivanan**
It contains 0.48% bupivacaine and 1.26000 norepinephrine. Bupivanan is an effective alternative to TAC and lidocaine infiltration for local anesthesia during laceration repair, especially on the face and scalp.[29]

**ELA-max**
It contains 4 or 5% (ELA-max 5) lignocaine cream in a liposomal matrix and is FDA-approved for the temporary relief of pain resulting from minor cuts and abrasions. ELA-max 5 is marketed for temporary relief of anorectal pain. ELA-max is applied to intact skin for 15-40 min with or without occlusion and provides a longer duration of anesthesia compared to nonliposomal preparations. Maximum area of application is 600 cm². In children weighing less than 20 kg, a single application of ELA-max cream should not be applied to an area larger than 100 cm².[30]

**Betacaine-LA**
It contains lignocaine, prilocaine and phenylephrine. Betacaine-LA is a proprietary anesthetic and exact concentration of its ingredients is a trade secret. The pocket insert of the product reports concentrations of lignocaine and prilocaine to be 4 times that of EMLA and so, it should not be applied to an area larger than 300 cm² in adults and is not advocated for use in children.[30]

**4% tetracaine (amethocaine)**
It is a long acting ester anesthetic in lecithin gel base, with a recommended application time of 30-min under occlusive dressing and maximum dose limit of 50 mg.[30]

**Topicaine**
Topicaine is 4% lignocaine in a gel microemulsion drug delivery system. The recommended application time by the manufacturers is 30-60 min. The maximum area of application is 600 cm² in adults and 100 cm² in children.[30]

**S-Caine Patch™ and local anesthetic peel**
The patch (manufactured by ZARS, Inc., Salt Lake City, UT, US) contains a 1:1 eutectic mixture of 70 mg lignocaine and 70 mg tetracaine base, with a disposable, oxygen activated heating element, which helps in accelerating transcutaneous delivery and analgesic effect of local anesthetics. The heating element generates a controlled level of heating (39°C-41°C) over a period of 2 h.[31,32]

**Lidoderm patch**
Lidoderm is comprised of an adhesive material containing 5% lignocaine. Each adhesive patch contains 700 mg of lignocaine (50 mg/g adhesive) in an aqueous base. It has been recently approved by the FDA for the treatment of pain caused by postherpetic neuralgia.

**Proparacaine or proxymetacaine**
About 0.5% solution is suitable for ophthalmic use. With a single drop, the onset of anesthesia usually begins within 30 s, the maximum anesthetic effect is achieved at 5-min and duration of corneal anesthesia is 15-25 min.

**Miscellaneous agents with topical anesthetic potential**
8-10% capsaicin[33] (act on transient receptor potential vanilloid 1, i.e., the transient receptor potential channel of the vanilloid receptor family subtype 1); tetradoxin,[34,35] 0.8% nalbuphine,[36] ethyl chloride spray,[37] etc.

**Clinical applications**
a. For local analgesia on intact skin-EMLA, 4% tetracaine, S-Caine Patch™.
b. Minimize discomfort prior to injections or before intravenous and arterial line\textsuperscript{38} access—EMLA, 4% tetracaine.

c. For symptomatic relief of chronic pain—heated lidocaine/tetracaine patch has potential utility for managing myofascial trigger points.\textsuperscript{39} Successful treatment of trigeminal neuralgia by topical anesthetic oxybuprocaine or proxymetacaine instilled in the eye of the affected side is also reported.\textsuperscript{40,41}

d. To relieve pruritus and pain due to minor burns, skin eruptions (e.g., herpes, sunburn, insect bites), stings, poison ivy, and minor cuts and scratches—EMLA, lidocaine, epinephrine, and tetracaine (LET), bupivanor, ELA-max.

e. To assist awake fiberoptic intubation—topical application, “spray as you go” technique, using MADgic device etc., 2% or 4% lignocaine.

f. In ophthalmology and optometry—0.5% proparacaine, 0.4% oxybuprocaine, 2% lignocaine aqueous gel and drops, 0.5% tetracaine.

g. To numb the outermost layers of the cornea and conjunctiva to:
   1. Perform a contact/applanation tonometry.
   2. Perform a Schirmer’s test.
   3. Remove small foreign bodies.
   4. During procedures as cryotherapy, shave biopsy, curettage of molluscum contagiosum, and laceration repair.
   5. Cataract phacoemulsification and minor laser surgeries.
   6. Intravitreal injection.\textsuperscript{42}

h. Otorhinolaryngology, for the day care and office based procedures\textsuperscript{43} like:
   1. Topical anesthesia of the tympanic membrane for tympanocentesis; myringotomy; transtympanic injection of gentamicin or steroids; and pressure equalizing tube placement, removal, or manipulation—using topical 80-90% liquefied phenol\textsuperscript{44} (provides an effective full-thickness analgesia with an immediate effect), a solution of 8% tetracaine base in 70% isopropyl alcohol\textsuperscript{45} or EMLA.\textsuperscript{46}
   2. Indications in nasal cavity include examination using rigid or flexible endoscopes, nasal debridement, control of epistaxis, treatment of nasal fractures,\textsuperscript{47} and management of abscesses and hematomas. Commonly administered in conjunction with a vasoconstricting substance such as 0.05% oxymetazoline for decongestion of mucosal edema.

i. For superficial dermatologic, esthetic, and laser procedures like venipuncture,\textsuperscript{49} hair and warts removal, split thickness skin graft harvesting,\textsuperscript{50} shave or excision biopsy, dermabrasion for tattoo removal, venous leg ulcer debridement, curettage and electrosurgery, treatment of port-wine stains etc.—EMLA 5%.

j. For minor penile surgery like circumcision, short frenulum plasty, meatotomy, fulguration of penile and urethral warts. Also for, temporary relief of premature ejaculation when applied to the glans of the penis.\textsuperscript{51}—EMLA 5%, benzocaine.

Contraindications

Ester group topical anesthetics are contraindicated in patients with known allergy to PABA, sulfonamides and hair dyes.

Adverse effects

Burning or stinging at the administration site.

Systemic toxicity—due to excess dosage, repeated use, particularly in patients on risk like infants or children or elderly, or patients with liver disease etc. Manifestations can be as follows:

- Nonspecific-metallic taste, circumoral numbness, diplopia, tinnitus, dizziness.
- Central nervous system (CNS): High plasma concentration can produce CNS excitation (agitation, confusion, muscle twitching, seizure), or CNS depression (drowsiness, obtundation, coma or respiratory arrest). Solutions that contain epinephrine may add to the CNS stimulatory effect.
- Cardiovascular: Hypertension, tachycardia, ventricular arrhythmias (ventricular tachycardia, torsades de pointes, ventricular fibrillation, or progressive hypotension, conduction block, bradycardia or asystole. Local anesthetics that contain epinephrine may cause hypertension, tachycardia, and angina.
• Treatment as per local anesthetic systemic toxicity treatment guidelines[52] of the American Society of Regional Anesthesia and Pain Medicine (ASRA) and encompasses airway management, cardiovascular support, seizure suppression and use of 20% intralipid.

• Allergic reaction to local anesthetics - local anesthetics with a PABA ester-type structure seem to cause most anesthesia-related allergic reactions.

• Gag-reflex suppression may occur with oral administration.

• Methemoglobinemia (with prilocaine[53] and benzocaine[54]) - signs and symptoms of methemoglobinemia (methemoglobin >1%) include dyspnea, cyanosis, headache, fatigue, exercise intolerance, dizziness and loss of consciousness. Arterial blood with elevated methemoglobin shows a characteristic chocolate-brown color. Severe methemoglobinemia (methemoglobin >50%) manifests as dysrhythmias, seizures, coma and death (>70%). Treatment includes supplemental oxygen, hyperbaric oxygen therapy, exchange transfusion and intravenous administration of the antidote, 1% methylene blue.[55]

• Others - skin discoloration, swelling, neuritis, tissue necrosis and sloughing etc.

Because the risk of adverse events with improper application is real, physicians must exercise caution and good judgment while using topical anesthetics.

Conclusion

Topical anesthetics play an important role in decreasing the pain associated with ophthalmological, superficial dermatological, aesthetic and laser procedures, minor surgeries, venipuncture etc. With very wide varieties of agents and delivery devices being improvised upon every day, it seems time is not far off when we can completely abolish use of infiltrative local anesthesia. But, users should be well aware about the pharmacology of the agents being used and possible adverse events.

References

1. Biscoping J, Bachmann-Mennenga MB. Local anesthetics from ester to isomer. Anesthesiol Intensivmed Notfallmed Schmerzther 2000;35:285-92.

2. Jackson T, McClure HA. Pharmacology of local anesthetics. Ophthalmol Clin North Am 2006;19:155-61.

3. Covino BG. Local anesthesia 1. N Engl J Med 1972;286:975-83.

4. Covino BG. Local anesthesia 2. N Engl J Med 1972;286:1035-42.

5. Covino BG. Local anesthetic agents for peripheral nerve blocks. Anaesthescist 1980;29:33-7.

6. Covino BG. Physiology and pharmacology of local anesthetic agents. Anesth Prog 1981;28:98-104.

7. Suuronen R, Kanerva L. Contact allergy and cross-reactions caused by prilocaine. Am J Contact Dermat 1997;8:231-5.

8. Fuzier R, Lapeyre-Mestre M, Merdes PM, Nicolas JF, Benoit Y, Didier A, et al. Immediate- and delayed-type allergic reactions to amide local anesthetics: Clinical features and skin testing. Pharmacoepidemiol Drug Saf 2009;18:595-601.

9. Kluger N, Raison-Peyron N, Michot C, Guillot B, Bessis D. Acute bullous irritant contact dermatitis caused by EMLA® cream. Contact Dermatitis 2011;65:181-3.

10. Mackie BS, Mackie LE. The PABA story. Australas J Dermatol 1999;40:51-3.

11. Adriani J, Dalili H. Penetration of local anesthetics through epithelial barriers. Anesth Analg 1971;50:834-41.

12. Cázare-Delgalajo J, Naik A, Kalia YN, Quintanar-Guerrero D, Ganae-Quintanar A. Skin permeation enhancement by surose esters: A pH-dependent phenomenon. Int J Pharm 2005;297:204-12.

13. Shokri J, Nokhodchi A, Dashbolaghi A, Hassan-Zadeh D, Ghaforian T, Barzegar Jalali M. The effect of surfactants on the skin penetration of diazepam. Int J Pharm 2001;228:99-107.

14. Tian W, Hu Q, Xu Y, Xu Y. Effect of soybean-lecithin as an enhancer of buccal mucosa absorption of insulin. Biomed Mater Eng 2012;22:171-8.

15. Shipston EA. New delivery systems for local anesthetics-part 2. Anesthesiol Res Pract 2012;2012:289373.

16. Greenbaum SS. Iontophoresis as a tool for anesthesia in dermatologic surgery: An overview. Dermatol Surg 2001;27:1027-30.

17. Kanebako M, Inagi T, Takayama K. Transdermal delivery of indomethacin by iontophoresis. Biol Pharm Bull 2002;25:779-82.

18. Sammeta SM, Vaka SR, Murthy SN. Transdermal drug delivery enhanced by low voltage electropulstion (IVE). Pharm Dev Technol 2009;14:159-64.

19. Wallace MS, Ridgeway B, Jun E, Schulteis G, Rabussay D, Zhang L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: An evaluation of skin anesthesia. Reg Anesth Pain Med 2001;26:229-38.

20. Zempsky WT, Robbins B, McKay K. Reduction of topical anesthetic onset time using ultrasound: A randomized controlled trial prior to venipuncture in young children. Pediatr Med 2008;9:795-802.

21. Sammeta SM, Repka MA, Narasimha Murthy S. Magnetophoresis in combination with chemical enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2011;37:1076-82.

22. Baron ED, Harris L, Redpath WS, Shapiro H, Hetzel F, Morley G, et al. Laser-assisted penetration of topical anesthetic in adults. Arch Dermatol 2003;139:1288-90.

23. Duan D, Moekcly C, Gysbers J, Novak C, Prochnow G, Siebenaler K, et al. Enhanced delivery of topically-applied formulations following skin pre-treatment with a hand-applied, plastic microneedle array. Curr Drug Deliv 2011;8:557-65.

24. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 1976;295:765-70.

25. Fendler JH, Romero A. Liposomes as drug carriers. Life Sci 1977;20:1109-20.

26. Lieb LM, Ramachandran C, Egbaria K, Weiner N. Topical delivery . Drug Dev Ind Pharm 1977;20:1109-20.

27. Fisher R, Hung O, Mezei M, Stewart R. Topical anesthesia of intact skin: An overview. Dermatol Surg 2001;27:1027-30.

28. Kundu S, Achar S. Principles of office anesthesia: Part II. Topical anesthesia. Am Fam Physician 2002;66:99-102.

29. Smith GA, Strausbaugh SD, Harbeck-Weber C, Shields BJ, Powers JD, Hackenberg D. Comparison of topical anesthetics without cocaine to tetracaine-adrenaline-coacine and lidocaine infiltration during...
repair of lacerations: Bupivacaine-norepinephrine is an effective new topical anesthetic agent. Pediatrics 1996;97:301-7.
30. Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anesthetics update: EMLA and beyond. Dermatol Surg 2001;27:1019-26.
31. Sethna NF, Vergese ST, Hannallah RS, Solodiuk JC, Zurakowski D, Berde CB. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology 2005;102:403-8.
32. Sawyer J, Febbraro S, Masud S, Ashburn MA, Campbell JC. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth 2009;102:210-5.
33. Haanpää M, Treede RD. Capsaicin for neuropathic pain: Linking traditional medicine and molecular biology. Eur Neurol 2012;68:264-75.
34. Schwartz DM, Fields HL, Duncan KG, Duncan JL, Jones MR. Experimental study of tetrodotoxin, a long-acting topical anesthetic. Am J Ophthalmol 1998;125:481-7.
35. Wang L, Shankarappa SA, Tong R, Ciolino JB, Tsui JH, Chiang HH, et al. Topical drug formulations for prolonged corneal anesthesia. Cornea 2013;32:1040-5.
36. Lee CH, Lin SL, Chi TT, Chang SH, Wang HC. Effect of topical administration of 0.8% nalbuphine on the cornea in dogs after phacoemulsification. J Vet Med Sci 2013;75:1041-7.
37. Soueid A, Richard B. Ethyl chloride as a cryoanalgesic in pediatrics. J Appl Pediatr Pharmacol 2007;23:380-3.
38. Gambrell J, Schaal S. Topical anesthetic for intravitreal injection. Expert Opin Drug Deliv 2012;9:731-3.
39. Jourdy DN, Kacker A. Regional anesthesia for office-based procedures in otorhinolaryngology. Anesthesiol Clin 2010;28:457-68.
40. Vassilouthis J. Relief of trigeminal neuralgia by proparacaine. J Neurosurg 1995;82:699-700.
41. Spaziante R, Cappabianca P, Saini M, de Divitiis E. Topical anesthetic. Am J Ophthalmol 1998;125:481-7.
42. Adams V, Marley J, McCarroll C. Prilocaine induced methaemoglobinemia: A Review and Recommendations for Management. J Cardiothorac Vasc Anesth 2014;28:1055-9.
43. Jourdy DN, Kacker A. Regional anesthesia for office-based procedures in otorhinolaryngology. Anesthesiol Clin 2010;28:457-68.
44. Weisskopf A. Phenol anesthesia for myringotomy. Laryngoscope 1983;93:114.
45. Hoffman RA, Li CL. Tetracaine topical anesthesia for myringotomy. Laryngoscope 2001;111:1636-8.
46. Luotonen J, Laitakari K, Karjalainen H, Jokinen K. EMLA in local anaesthesia of the tympanic membrane. Acta Otolaryngol Suppl 1992;492:67-7.
47. Azighечи S, Baradaranfar MH, Akbari SA. Reduction of nasal bone fractures: A comparative study of general, local, and topical anesthetic techniques. J Craniofac Surg 2009;20:382-4.
48. Resch K, Schilling C, Borchert BD, Klatzko M, Uden D. Topical anesthesia for pediatric lacerations: A randomized trial of lidocaine-epinephrine-tetracaine solution versus gel. Ann Emerg Med 1998;32:693-7.
49. Hopkins CS, Buckley CJ, Bush GH. Pain-free injection in infants. Use of a lignocaine-prilocaine cream to prevent pain at intravenous induction of general anaesthesia in 1-5-year-old children. Anaesthesia 1988;43:198-201.
50. Goodacre TE, Sanders R, Watts DA, Stoker M. Split skin grafting using topical local anaesthesia (EMLA): A comparison with infiltrated anaesthesia. Br J Plast Surg 1988;41:533-8.
51. Gyftopoulos KI. The efficacy and safety of topical EMLA cream application for minor surgery of the adult penis. Urol Ann 2012;4:145-9.
52. Neal JM, Bernards CM, Butterworth JF 4th, Di Gregorio G, Drasner K, Hejtmamek MR, et al. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med 2010;35:152-61.
53. Adams V, Marley J, McCarron C. Prilocaine induced methaemoglobinemia in a medically compromised patient. Was this an inevitable consequence of the dose administered? Br Dent J 2007;203:585-7.
54. Vallurupalli S, Manchanda S. Risk of acquired methemoglobinemia with different topical anesthetics during endoscopic procedures. Local Reg Anesth 2011;4:25-8.
55. Cortazzo JA, Lichtman AD. Methemoglobinemia: A Review and Recommendations for Management. J Cardiothorac Vasc Anesth 2014;28:1055-9.

How to cite this article: Kumar M, Chawla R, Goyal M. Topical anesthesia. J Anaesthesiol Clin Pharmacol 2015;31:450-6.

Source of Support: Nil, Conflicts of Interest: None declared.

**“QUICK RESPONSE CODE” LINK FOR FULL TEXT ARTICLES**

The journal issue has a unique new feature for reaching to the journal’s website without typing a single letter. Each article on its first page has a “Quick Response Code”. Using any mobile or other hand-held device with camera and GPRS/other internet source, one can reach to the full text of that particular article on the journal’s website. Start a QR-code reading software (see list of free applications from http://tinyurl.com/yb2h2tc) and point the camera to the QR-code printed in the journal. It will automatically take you to the HTML full text of that article. One can also use a desktop or laptop with web camera for similar functionality. See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.